331 related articles for article (PubMed ID: 19525862)
1. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD.
Savvidou S; Hytiroglou P; Orfanou-Koumerkeridou H; Panderis A; Frantzoulis P; Goulis J
J Clin Gastroenterol; 2009 Sep; 43(8):765-72. PubMed ID: 19525862
[TBL] [Abstract][Full Text] [Related]
2. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
[TBL] [Abstract][Full Text] [Related]
3. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.
Targher G; Bertolini L; Rodella S; Zoppini G; Scala L; Zenari L; Falezza G
Clin Endocrinol (Oxf); 2006 Jun; 64(6):679-83. PubMed ID: 16712671
[TBL] [Abstract][Full Text] [Related]
4. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
Bugianesi E; Marchesini G; Gentilcore E; Cua IH; Vanni E; Rizzetto M; George J
Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
[TBL] [Abstract][Full Text] [Related]
5. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.
Hossain N; Afendy A; Stepanova M; Nader F; Srishord M; Rafiq N; Goodman Z; Younossi Z
Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1224-9, 1229.e1-2. PubMed ID: 19559819
[TBL] [Abstract][Full Text] [Related]
6. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects.
Musso G; Gambino R; Bo S; Uberti B; Biroli G; Pagano G; Cassader M
Diabetes Care; 2008 Mar; 31(3):562-8. PubMed ID: 18056890
[TBL] [Abstract][Full Text] [Related]
7. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.
Harrison SA; Oliver D; Arnold HL; Gogia S; Neuschwander-Tetri BA
Gut; 2008 Oct; 57(10):1441-7. PubMed ID: 18390575
[TBL] [Abstract][Full Text] [Related]
9. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease.
Targher G; Bertolini L; Rodella S; Zoppini G; Zenari L; Falezza G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):337-41. PubMed ID: 16487446
[TBL] [Abstract][Full Text] [Related]
10. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease.
Machado MV; Coutinho J; Carepa F; Costa A; Proença H; Cortez-Pinto H
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1166-72. PubMed ID: 22735605
[TBL] [Abstract][Full Text] [Related]
11. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease.
Nobili V; Alkhouri N; Alisi A; Ottino S; Lopez R; Manco M; Feldstein AE
Clin Gastroenterol Hepatol; 2009 May; 7(5):575-9. PubMed ID: 19268270
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.
Kaneda H; Hashimoto E; Yatsuji S; Tokushige K; Shiratori K
J Gastroenterol Hepatol; 2006 Sep; 21(9):1459-65. PubMed ID: 16911693
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).
Yoneda M; Yoneda M; Mawatari H; Fujita K; Endo H; Iida H; Nozaki Y; Yonemitsu K; Higurashi T; Takahashi H; Kobayashi N; Kirikoshi H; Abe Y; Inamori M; Kubota K; Saito S; Tamano M; Hiraishi H; Maeyama S; Yamaguchi N; Togo S; Nakajima A
Dig Liver Dis; 2008 May; 40(5):371-8. PubMed ID: 18083083
[TBL] [Abstract][Full Text] [Related]
15. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.
Haukeland JW; Konopski Z; Linnestad P; Azimy S; Marit Løberg E; Haaland T; Birkeland K; Bjøro K
Scand J Gastroenterol; 2005 Dec; 40(12):1469-77. PubMed ID: 16293559
[TBL] [Abstract][Full Text] [Related]
16. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.
Yoneda M; Iwasaki T; Fujita K; Kirikoshi H; Inamori M; Nozaki Y; Maeyama S; Wada K; Saito S; Terauchi Y; Nakajima A
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S15-21. PubMed ID: 17331160
[TBL] [Abstract][Full Text] [Related]
17. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test.
Park GJ; Wiseman E; George J; Katelaris PH; Seow F; Fung C; Ngu MC
J Gastroenterol Hepatol; 2011 Sep; 26(9):1411-6. PubMed ID: 21557768
[TBL] [Abstract][Full Text] [Related]
19. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis.
Manco M; Bedogni G; Marcellini M; Devito R; Ciampalini P; Sartorelli MR; Comparcola D; Piemonte F; Nobili V
Gut; 2008 Sep; 57(9):1283-7. PubMed ID: 18218674
[TBL] [Abstract][Full Text] [Related]
20. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension.
Sorrentino P; Terracciano L; D'Angelo S; Ferbo U; Bracigliano A; Vecchione R
Am J Gastroenterol; 2010 Feb; 105(2):336-44. PubMed ID: 19861959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
